3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Prostatic Neoplasms
120
Lymphoma
90
Lymphoma, Large B-Cell, Diffuse
79
Precursor Cell Lymphoblastic Leukemia-Lymphoma
35
Burkitt Lymphoma
31
Leukemia
27
Multiple Myeloma
26
Lymphoma, Non-Hodgkin
26
Lymphoma, Follicular
26
Hodgkin Disease
24
Lymphoma, Mantle-Cell
18
Neoplasms
16
Lymphoma, T-Cell, Peripheral
16
Lymphoma, B-Cell
14
Lymphoma, Large-Cell, Immunoblastic
12
Lymphoma, Large-Cell, Anaplastic
11
Dendritic Cell Sarcoma, Interdigitating
10
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
9
Recurrence
8
Lymphoma, B-Cell, Marginal Zone
8
Leukemia, Lymphocytic, Chronic, B-Cell
8
Neoplasms, Plasma Cell
7
Neoplasm Metastasis
7
Waldenstrom Macroglobulinemia
6
Primary Myelofibrosis
6
Lymphoma, T-Cell
6
Immunoblastic Lymphadenopathy
6
HIV Infections
5
Graft vs Host Disease
5
Blast Crisis
5
Interventions
Mycophenolic Acid
2
vedolizumab
1
Ursodeoxycholic Acid
1
Steroids
1
Sofosbuvir
1
Ribavirin
1
Prednisone
1
Photopheresis
1
Methylprednisolone Hemisuccinate
1
Methylprednisolone
1
Methoxsalen
1
Infliximab
1
Azathioprine
1
Adrenal Cortex Hormones
1
3-(2-(2-tert-butylphenylaminooxalyl)aminopropionylamino)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Hepatitis
×
Prednisone
×
Clear all
NCT04810156
2022-12-14
I-HEP
Herlev Hospital
Phase 2
Unknown
60 enrolled